Display options
Share it on
Full text links
HighWire Free PMC Article

Proc Natl Acad Sci U S A. 1992 Jan 01;89(1):137-41. doi: 10.1073/pnas.89.1.137.

Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein.

Proceedings of the National Academy of Sciences of the United States of America

D Teitelbaum, R Milo, R Arnon, M Sela

Affiliations

  1. Department of Chemical Immunology, Weizmann Institute of Science, Rehovot, Israel.

PMID: 1370347 PMCID: PMC48191 DOI: 10.1073/pnas.89.1.137
Free PMC Article

Abstract

Copolymer 1 (Cop 1) is a synthetic basic random copolymer of amino acids that has been shown to be effective in suppression of experimental allergic encephalomyelitis and has been proposed as a candidate drug for multiple sclerosis. Cop 1 is immunologically cross reactive with myelin basic protein (BP) and was shown to inhibit murine BP-specific T-cell lines of various H-2 restrictions. In the present study these findings were extended to include human T-cell lines. Cop 1 competitively inhibited the proliferative responses and interleukin 2 secretion of six BP-specific T-cell lines and 13 clones with several DR restrictions and epitope specificities. Conversely, BP inhibited--albeit to a lesser extent--the response of all the Cop 1-specific T-cell lines and clones, irrespective of their DR restrictions. Another random copolymer of tyrosine, glutamic acid, and alanine, denoted TGA, had no effect on these lines. Neither Cop 1 nor BP inhibited the response of lines and clones specific for purified protein derivative. Cop 1 and BP exerted their cross-inhibitory effects only in the presence of antigen-presenting cells. These results suggest that Cop 1 can compete with BP for the binding to human major histocompatibility complex molecules. In view of recent studies implicating BP reactivity in multiple sclerosis, these findings suggest a possible mechanism for the beneficial effect of Cop 1 in this disease.

Similar articles

Cited by

References

  1. Immunol Today. 1991 Aug;12(8):277-82 - PubMed
  2. Immunochemistry. 1976 Apr;13(4):333-7 - PubMed
  3. Immunol Today. 1990 Jan;11(1):21-4 - PubMed
  4. Eur J Immunol. 1973 May;3(5):273-9 - PubMed
  5. FEBS Lett. 1970 May 1;7(4):317-320 - PubMed
  6. Cell. 1989 Oct 20;59(2):247-55 - PubMed
  7. Eur J Immunol. 1971 Aug;1(4):242-8 - PubMed
  8. J Neurosci Res. 1989 Jun;23(2):207-16 - PubMed
  9. Eur J Immunol. 1981 Mar;11(3):195-9 - PubMed
  10. Clin Immunol Immunopathol. 1974 Nov;3(2):256-62 - PubMed
  11. Nature. 1990 Jul 12;346(6280):183-7 - PubMed
  12. Proc Natl Acad Sci U S A. 1991 Nov 1;88(21):9738-42 - PubMed
  13. Science. 1965 Oct 8;150(3693):178-85 - PubMed
  14. Science. 1990 Feb 9;247(4943):718-21 - PubMed
  15. Immunol Today. 1989 Sep;10(9):299-304 - PubMed
  16. Biochem J. 1962 Oct;85:223-35 - PubMed
  17. Proc Natl Acad Sci U S A. 1988 Dec;85(24):9724-8 - PubMed
  18. Eur J Immunol. 1973 May;3(5):279-86 - PubMed
  19. J Immunol. 1979 Nov;123(5):2156-60 - PubMed
  20. N Engl J Med. 1977 Oct 20;297(16):850-3 - PubMed
  21. Eur J Immunol. 1991 Jun;21(6):1391-5 - PubMed
  22. N Engl J Med. 1987 Aug 13;317(7):408-14 - PubMed
  23. Cell Immunol. 1983 Oct 15;81(2):435-40 - PubMed
  24. Neurology. 1990 Nov;40(11):1770-6 - PubMed
  25. J Neuroimmunol. 1989 Jun;23(1):55-66 - PubMed
  26. Int Immunol. 1990;2(8):735-42 - PubMed
  27. Annu Rev Immunol. 1990;8:579-621 - PubMed
  28. Neurology. 1991 Aug;41(8):1317-9 - PubMed
  29. Nature. 1986 Nov 20-26;324(6094):260-2 - PubMed
  30. Neurology. 1986 Jan;36(1):92-4 - PubMed
  31. J Neuroimmunol. 1991 Aug;33(2):97-102 - PubMed
  32. Clin Immunol Rev. 1981-1982;1(4):581-697 - PubMed
  33. Neurology. 1985 Dec;35(12):1754-9 - PubMed
  34. J Neuroimmunol. 1989 Oct;24(3):217-22 - PubMed
  35. Proc Natl Acad Sci U S A. 1991 Nov 1;88(21):9528-32 - PubMed

Substances

MeSH terms

Publication Types

LinkOut - more resources